MCID: VSC007
MIFTS: 63

Vascular Disease

Categories: Blood diseases, Cardiovascular diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Vascular Disease

MalaCards integrated aliases for Vascular Disease:

Name: Vascular Disease 12 15 17
Vascular Diseases 54 42 44 15 71
Spinal Cord Ischemia 44 17 71
Spinal Cord Vascular Diseases 44 71
Aneurysm 44 71
Vascular Tissue Disease 12
Vascular Anomaly 54

Classifications:



External Ids:

Disease Ontology 12 DOID:178
ICD9CM 34 442.9
ICD10 32 I72.9
UMLS 71 C0002940 C0042373 C0752127 more

Summaries for Vascular Disease

MedlinePlus : 42 What are vascular diseases? Your vascular system is your body's network of blood vessels. It includes your Arteries, which carry oxygen-rich blood from your heart to your tissues and organs Veins, which carry the blood and waste products back to your heart Capillaries, which are tiny blood vessels that connect your small arteries to your small veins. The walls of the capillaries are thin and leaky, to allow for an exchange of materials between your tissues and blood. Vascular diseases are conditions which affect your vascular system. They are common and can be serious. Some types include Aneurysm - a bulge or "ballooning" in the wall of an artery Atherosclerosis - a disease in which plaque builds up inside your arteries. Plaque is made up of fat, cholesterol, calcium, and other substances found in the blood. Blood clots, including deep vein thrombosis and pulmonary embolism Coronary artery disease and carotid artery disease, diseases that involve the narrowing or blockage of an artery. The cause is usually a buildup of plaque. Raynaud's disease - a disorder that causes the blood vessels to narrow when you are cold or feeling stressed Stroke - a serious condition that happens when blood flow to your brain stops. Varicose veins - swollen, twisted veins that you can see just under the skin Vasculitis - inflammation of the blood vessels What causes vascular diseases? The causes of vascular diseases depend on the specific disease. These causes include Genetics Heart diseases such as high cholesterol and high blood pressure Infection Injury Medicines, including hormones Sometimes the cause is unknown. Who is at risk for vascular diseases? The risk factors for vascular diseases can vary, depending on the specific disease. But some of the more common risk factors include Age - your risk of some diseases goes up as you get older Conditions that can affect the heart and blood vessels, such as diabetes or high cholesterol Family history of vascular or heart diseases Infection or injury that damages your veins Lack of exercise Obesity Pregnancy Sitting or standing still for long periods of time Smoking What are the symptoms of vascular diseases? The symptoms for each disease are different. How are vascular diseases diagnosed? To make a diagnosis, your health care provider will do a physical exam and ask about your symptoms and medical history. You may have imaging tests and/or blood tests. How are vascular diseases treated? Which treatment you get depends on which vascular disease you have and how severe it is. Types of treatments for vascular diseases include Lifestyle changes, such as eating a heart-healthy diet and getting more exercise Medicines, such as blood pressure medicines, blood thinners, cholesterol medicines, and clot-dissolving drugs. In some cases, providers use a catheter to send medicine directly to a blood vessel. Non-surgical procedures, such as angioplasty, stenting, and vein ablation Surgery Can vascular diseases be prevented? There are steps you can take to help prevent vascular diseases: Make healthy lifestyle changes, such as eating a heart-healthy diet and getting more exercise Don't smoke. If you are already a smoker, talk to your health care provider for help in finding the best way for you to quit. Keep your blood pressure and cholesterol in check If you have diabetes, control your blood sugar Try not to sit or stand for up long periods of time. If you do need to sit all day, get up and move around every hour or so. If you traveling on a long trip, you can also wear compression stockings and regularly stretch your legs.

MalaCards based summary : Vascular Disease, also known as vascular diseases, is related to peripheral vascular disease and intracranial berry aneurysm, and has symptoms including angina pectoris, chest pain and edema. An important gene associated with Vascular Disease is MIR145 (MicroRNA 145), and among its related pathways/superpathways are Fluid shear stress and atherosclerosis and Folate Metabolism. The drugs Eplerenone and Citalopram have been mentioned in the context of this disorder. Affiliated tissues include endothelial, kidney and smooth muscle, and related phenotypes are cardiovascular system and homeostasis/metabolism

Disease Ontology : 12 A cardiovascular system disease that primarily affects the blood vessels which includes the arteries, veins and capillaries that carry blood to and from the heart.

Wikipedia : 74 Vascular disease is a class of diseases of the blood vessels - the arteries and veins of the circulatory... more...

Related Diseases for Vascular Disease

Diseases in the Vascular Disease family:

Rare Vascular Disease

Diseases related to Vascular Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2250)
# Related Disease Score Top Affiliating Genes
1 peripheral vascular disease 33.8 VWF VEGFA VCAM1 SERPINE1 SELP MTHFR
2 intracranial berry aneurysm 33.4 VWF VCAM1 NOS3 EDN1 CRP APOE
3 hepatic vascular disease 32.9 VWF VEGFA SERPINE1 NOS3 MTHFR MIR214
4 buerger disease 32.9 VEGFA VCAM1 PON1 EDN1 CRP
5 retinal vascular disease 32.8 VEGFA NOS3 MTHFR MIR21 INS ACE
6 arteriosclerosis 32.8 VCAM1 SERPINE1 SELP PON1 NOS3 MIR21
7 cerebrovascular disease 32.7 VWF VCAM1 SERPINE1 SELP PON1 MTHFR
8 patent foramen ovale 32.6 VWF SERPINE1 MTHFR EDN1 CRP ACE
9 portal vein thrombosis 32.6 SERPINE1 SELP MTHFR CRP
10 polycystic kidney disease 32.5 VEGFA NOS3 INS EDN1 ACE
11 vasculitis 32.5 VWF VCAM1 SELP CRP
12 thrombosis 32.5 VWF SERPINE1 SELP MTHFR
13 vein disease 32.5 VWF VEGFA SERPINE1 SELP MTHFR INS
14 fabry disease 32.4 VEGFA VCAM1 PON1 NOS3 CRP
15 diabetic angiopathy 32.4 VWF NOS3 MTHFR INS EDN1
16 ischemia 32.4 VEGFA SELP PON1 NOS3 MIR21 EDN1
17 carpal tunnel syndrome 32.3 VEGFA INS ACE
18 henoch-schoenlein purpura 32.3 VCAM1 CRP ACE
19 intermittent claudication 32.3 VWF VEGFA SERPINE1 SELP CRP ACE
20 chronic thromboembolic pulmonary hypertension 32.2 EDN1 CRP
21 peripheral artery disease 32.2 VWF VEGFA VCAM1 SELP NOS3 EDN1
22 atherosclerosis susceptibility 32.1 VWF VEGFA VCAM1 SERPINE1 SELP PON1
23 homocysteinemia 32.1 VWF VCAM1 SERPINE1 PON1 NOS3 MTHFR
24 cholesterol embolism 32.1 CRP ACE
25 pulmonary hypertension 32.0 VWF VEGFA SERPINE1 SELP NOS3 MIR21
26 lipid metabolism disorder 32.0 SERPINE1 PON1 INS CRP APOE APOB
27 carotid stenosis 32.0 VWF VEGFA VCAM1 SELP NOS3 MTHFR
28 aortic aneurysm, familial abdominal, 1 32.0 VCAM1 SERPINE1 NOS3 CRP APOE ACE
29 hypercholesterolemia, familial, 1 32.0 NOS3 INS CRP APOE APOB ACE
30 coronary heart disease 1 31.9 SERPINE1 PON1 INS CRP APOE APOB
31 end stage renal disease 31.9 VEGFA PON1 NOS3 MTHFR INS CRP
32 vascular dementia 31.8 VEGFA PON1 MTHFR CRP APOE ACE
33 kidney disease 31.8 VEGFA VCAM1 SERPINE1 PON1 NOS3 MTHFR
34 chronic kidney disease 31.8 VEGFA VCAM1 SERPINE1 PON1 NOS3 MTHFR
35 pericardial effusion 31.8 VEGFA CRP ACE
36 carotid artery disease 31.7 PON1 CRP APOE APOB ACE
37 systemic scleroderma 31.7 SELP INS EDN1 CRP ACE
38 stroke, ischemic 31.7 VWF SERPINE1 SELP PON1 NOS3 MTHFR
39 hyperglycemia 31.7 VCAM1 SERPINE1 NOS3 INS APOB
40 limb ischemia 31.7 VWF VEGFA SERPINE1 NOS3 MIR21 EDN1
41 impotence 31.7 NOS3 INS EDN1 ACE
42 congestive heart failure 31.7 VEGFA NOS3 INS EDN1 CRP ACE
43 autosomal dominant polycystic kidney disease 31.6 VEGFA VCAM1 NOS3 INS EDN1 ACE
44 pulmonary embolism 31.6 VWF SERPINE1 MTHFR CRP ACE
45 aortic aneurysm 31.6 MIR21 MIR145 CRP APOE ACE
46 hypertriglyceridemia, familial 31.6 SERPINE1 INS APOE APOB
47 pre-eclampsia 31.6 VWF VEGFA VCAM1 SERPINE1 SELP PON1
48 angina pectoris 31.6 NOS3 INS EDN1 CRP ACE
49 mild cognitive impairment 31.5 MTHFR APOE ACE
50 diabetes mellitus 31.5 VWF VEGFA VCAM1 SERPINE1 SELP PON1

Graphical network of the top 20 diseases related to Vascular Disease:



Diseases related to Vascular Disease

Symptoms & Phenotypes for Vascular Disease

UMLS symptoms related to Vascular Disease:


angina pectoris, chest pain, edema, flushing, leg cramps, warm skin, vein pain

MGI Mouse Phenotypes related to Vascular Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.07 ACE APOB APOE CRP EDN1 INS
2 homeostasis/metabolism MP:0005376 10 ACE APOB APOE CRP EDN1 INS
3 liver/biliary system MP:0005370 9.61 ACE APOB APOE INS MTHFR NOS3
4 renal/urinary system MP:0005367 9.23 ACE APOE EDN1 INS NOS3 SELP

Drugs & Therapeutics for Vascular Disease

Drugs for Vascular Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 568)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Eplerenone Approved Phase 4 107724-20-9 150310 443872
2
Citalopram Approved Phase 4 59729-33-8 2771
3
Glyburide Approved Phase 4 10238-21-8 3488
4
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
5
Sevelamer Approved Phase 4 52757-95-6
6
Calcium acetate Approved, Investigational Phase 4 62-54-4
7
Vitamin K1 Approved, Investigational Phase 4 84-80-0 5284607
8
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
9
Testosterone enanthate Approved Phase 4 315-37-7 9416
10
Testosterone Approved, Investigational Phase 4 58-22-0 6013
11
Methyltestosterone Approved Phase 4 58-18-4 6010
12
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
13
Vorapaxar Approved Phase 4 618385-01-6
14
Iodine Approved, Investigational Phase 4 7553-56-2 807
15
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
16
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
17
Allopurinol Approved Phase 4 315-30-0 2094
18
Iloprost Approved, Investigational Phase 4 78919-13-8 6443959
19
Defibrotide Approved, Investigational Phase 4 83712-60-1
20
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
21
Acenocoumarol Approved, Investigational Phase 4 152-72-7 9052 54676537
22
Phenprocoumon Approved, Investigational Phase 4 435-97-2 9908 54680692
23
Racepinephrine Approved Phase 4 329-65-7 838
24
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
25
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
26
Evolocumab Approved Phase 4 1256937-27-5
27
Ramipril Approved Phase 4 87333-19-5 5362129
28
Bupivacaine Approved, Investigational Phase 4 38396-39-3, 2180-92-9 2474
29
Glucagon Approved Phase 4 16941-32-5
30
Liraglutide Approved Phase 4 204656-20-2 44147092
31
Desflurane Approved Phase 4 57041-67-5 42113
32
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
33
Abacavir Approved, Investigational Phase 4 136470-78-5 65140 441300
34
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
35
Darunavir Approved Phase 4 635728-49-3, 206361-99-1 213039
36
Dolutegravir Approved Phase 4 1051375-16-6 54726191
37
Zidovudine Approved Phase 4 30516-87-1 35370
38
Cobicistat Approved Phase 4 1004316-88-4
39
Rilpivirine Approved Phase 4 500287-72-9 6451164
40
Mycophenolic acid Approved Phase 4 24280-93-1 446541
41
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
42
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
43
Acyclovir Approved Phase 4 59277-89-3 2022
44
Rivaroxaban Approved Phase 4 366789-02-8
45
Bevacizumab Approved, Investigational Phase 4 216974-75-3
46
Morphine Approved, Investigational Phase 4 57-27-2 5288826
47
Paclitaxel Approved, Vet_approved Phase 4 33069-62-4 36314
48
Clevidipine Approved, Investigational Phase 4 167221-71-8
49
Acetaminophen Approved Phase 4 103-90-2 1983
50
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754

Interventional clinical trials:

(show top 50) (show all 2679)
# Name Status NCT ID Phase Drugs
1 Randomized Trial of Paclitaxel Eluting Balloon or Conventional Balloon for Treatment of In-Stent Restenosis of the Superficial Femoral Artery in Patients With Symptomatic Peripheral Artery Disease (ISAR-PEBIS) Unknown status NCT01083394 Phase 4
2 The Cook Zilver PTX Drug-eluting Stent Versus Bypass Surgery for the Treatment The Cook Zilver PTX Drug-eluting Stent Versus Bypass Surgery of Femoropopliteal TASC C&D Lesions Unknown status NCT01952457 Phase 4
3 Randomized Trial of Stenting After Dilation With or Without Paclitaxel Eluting Balloon or Atherectomy in Patients With Symptomatic Peripheral Artery Disease Unknown status NCT00986752 Phase 4
4 DCLI-II:Optimized Strategy for Diabetic Patients With Critical Limb Ischemia: A Multi-center, Randomized Controlled Trial and Registration Study(Part II) Unknown status NCT01173094 Phase 4
5 Optimized Strategy for Diabetic Patients With Critical Limb Ischemia: A Multi-center, Randomized Controlled Trial and Registration Study(Part I) Unknown status NCT01171703 Phase 4
6 Evaluation of Closed Incision Negative Pressure Device (Prevena) to Prevent Vascular Wound Complications Unknown status NCT02581904 Phase 4
7 The Effect of Immunonutrition on Outcome and Postoperative Recovery in Patients Undergoing Elective Surgical Repair of a Thoraco (Abdominal) Aneurysm Aorta Unknown status NCT00339053 Phase 4 Immunonutrition ( Impact)
8 Prophylactic Mesh Implantation After Abdominal Aortic Aneurysm Repair. A Prospective, Randomised, Controlled Study Unknown status NCT01353443 Phase 4
9 Eplerenone in the Management of Abdominal Aortic Aneurysms: A Proof-Of-Concept Randomised Controlled Trial Unknown status NCT02345590 Phase 4 Eplerenone
10 Comparative Study of Covered Stent With Coil Embolization in the Treatment of Cranial Internal Carotid Artery Aneurysm: A Nonrandomized Prospective Trial Unknown status NCT01029938 Phase 4
11 Multicenter Randomized Controlled Study of Intravitreal Ranibizumab and Triamcinolone Acetonide Combination Therapy Versus Ranibizumab Monotherapy in Patients With Polypoidal Choroidal Vasculopathy Unknown status NCT02806752 Phase 4 Triamcinolone Acetonide;Ranibizumab
12 In.Pact Flexion, a Physician Initiated Trial Investigating the Performance of the In.Pact Admiral Drug-eluting Balloon for the Treatment of Popliteal Lesions Unknown status NCT02678065 Phase 4
13 Effect of Topical Anesthesia on Patient's Pain Discomfort and Radial Artery Spasm in Transradial Catheterization Unknown status NCT03501212 Phase 4 Topical Anesthetic;Placebo
14 Randomized Controlled Trial to Evaluate Implanted Event Recorders for the First Diagnosis of Atrial Fibrillation in High-risk Patients Unknown status NCT01461434 Phase 4
15 The Study to Compare the Treatment of Stent and Prothesis Bypass in SFA Occlusions Unknown status NCT01147419 Phase 4
16 Exploratory Study to Assess the Efficacy of Escitalopram Versus Placebo in the Treatment of Depressive Syndrome in Alzheimer's Disease, Vascular Dementia and Mixed Vascular and Alzheimer's Dementia Unknown status NCT00229333 Phase 4 Escitalopram
17 A Randomized Controlled Trial Comparing Usual Care With a Multifactorial Intensified Intervention on Cardiovascular Risk Factors in Subjects With Arterial Peripheral Disease With and Without Diabetes. The Taulí Intervention Program (TIP). Unknown status NCT00144937 Phase 4 Stepwise therapy for dyslipidemia, hypertension and diabetes
18 Bedside Testing of the CYP2C19 Gene to Asses Effectiveness of Clopidogrel in Coronary Artery Disease Patients Treated With Percutaneous Coronary Intervention : Individualized Antiplatelet Drugs Treatment to Improve Prognosis Unknown status NCT01823185 Phase 4 clopidogrel;Ticagrelor or prasugrel
19 Paclitaxel Eluting Stent or Exercise for Thigh Atherosclerosis (PESETA) Unknown status NCT02033135 Phase 4
20 Platelets Induced Vasodilation, in Vitro and in Vivo Study in Patients With Arteriopathy and Healthy Subjects. Unknown status NCT00152646 Phase 4 placebo, aspirine, clopidogrel
21 Open-label, Non-randomized, Unmasked, Study of IAI in Patients Which Choroidal Neovascularization Secondary to Polypoidal Choroidal Vasculopathy (PCV) Unknown status NCT02092532 Phase 4 Rescue Intravitreal Aflibercept Injection
22 Excellence In Peripheral Artery Disease Thrombin Receptor Antagonist Intervention In Claudication Evaluation (XLPAD-TRACE Trial) Unknown status NCT02660866 Phase 4 Placebo + background APT + SMT;Vorapaxar 2.08 mg/d + background APT + SMT.
23 Early Warning and Optimization Strategy in Carotid Endarterectomy Unknown status NCT01210937 Phase 4
24 A Prospective, Randomized, Two Period, With an Intermediate Wash Out Period, Cross-over Study to Compare the Effects of Either Combined Therapy With Ramipril and Clopidogrel or Ramipril Monotherapy on Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Patients With Type 2 Diabetes and Diabetic Nephropathy Unknown status NCT01743014 Phase 4 Ramipril;Clopidogrel
25 Ramipril Treatment of Claudication: Oxidative Damage and Muscle Fibrosis Unknown status NCT02842424 Phase 4 Ramipril
26 Efficacy of Self-Expanding Nitinol S.M.A.R.T CONTROLTM Stent Versus Life Stent For The Atherosclerotic Femoro-Popliteal Arterial Disease : Prospective, Multicenter, Randomized, Controlled Trial (SENS-FP-2 Trial) Unknown status NCT01653600 Phase 4
27 The Efficacy Assessment of Intravitreal Injection of Conbercept in Patients With Polypoidal Choroidal Vasculopathy (PCV) Unknown status NCT03159884 Phase 4 Conbercept
28 Tailored Strategy for Residual Platelet Activity In Advanced Peripheral Artery Disease: New Optimal Management. Unknown status NCT01627431 Phase 4 Acetylsalicylic acid;Clopidogrel
29 Phase IV Clinical Trial (STAR Study) Extension Study of Conbercept Ophthalmic Injection for Treatment of Polypoid Choroidal Vasculopathy Unknown status NCT03244657 Phase 4 conbercept ophthalmic injection (0.5mg);conbercept ophthalmic injection (0.5mg)
30 SAFE (Sarpogrelate Anplone in Femoro-popliteal Artery Intervention Efficacy) Study : a Randomized Controlled Trial Unknown status NCT02959606 Phase 4 Sarpogrelate SR 300mg;Clopidogrel
31 A Randomised Controlled Trial of the Effectiveness of Acetazolamide in Reducing Cerebrospinal Fluid Pressure for Patients Undergoing Thoracic-abdominal Aortic Repair Unknown status NCT01889498 Phase 4 Acetazolamide
32 Randomized Comparison of Platelet Function Monitoring to Adjust Antiplatelet Therapy Versus a Common Antiplatelet Treatment for Intracranial Aneurysm Stent-assisted Coiling Unknown status NCT02224131 Phase 4 Aspirin and clopidogrel;Aspirin and clopidogrel
33 Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained Intracranial Lesions Unknown status NCT02478346 Phase 4 Fluorescein Sodium
34 Multicenter Clinical Study Assessing the Performance and the Safety of the Second Generation Antimicrobial Graft in the Abdominal Position Unknown status NCT00824109 Phase 4
35 Delayed Vasospasm After Aneurysm With the Standardization Treatment of Traditional Chinese Medicine Unknown status NCT01840761 Phase 4 herbal drug;placebo
36 The Role of Statins in Preventing Cerebral Vasospasm Secondary to Subarachnoid Hemorrhage Unknown status NCT01346748 Phase 4 statin
37 Glibenclamide in Aneurysmatic Subarachnoid Hemorrhage: A Prospective and Randomized Study Unknown status NCT03569540 Phase 4 Glibenclamide
38 A Prospective Randomized Multicenter Study of the Efficacy and Safety of Systematic Post -Dilatation With Noncompliant Balloon After Successful Drug-eluting Stent Implantation. IVUS Analysis. Unknown status NCT01103765 Phase 4
39 Thoracic Paravertebral Blocks Using a Combination of Ropivacaine and Dexmedetomidine Unknown status NCT03677115 Phase 4 Dexmedetomidine
40 SPIRIT V: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Coronary Artery Lesions Completed NCT01171820 Phase 4
41 SPIRIT V: A Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Coronary Artery Lesions Completed NCT00402272 Phase 4
42 Study of Pain, Anxiety, Complications Related to AV Fistula Cannulation in Chronic Hemodialysis Patients. A. Buttonhole vs. Rope Ladder Technique B. Catheters With Cylindrical Point vs. Catheters With Bevel Point in Rope Ladder Technique Completed NCT00544492 Phase 4
43 4-EVER Study - Physician-Initiated Trial Investigating the Safety of the Full 4F Endovascular Treatment Approach of Infra-Inguinal Arterial Stenotic Disease Completed NCT01413139 Phase 4
44 Femoral Artery In-Stent Restenosis (FAIR) Trial Completed NCT01305070 Phase 4
45 The GORE VIABAHN® Endoprosthesis With PROPATEN Bioactive Surface Versus Plain Old Balloon Angioplasty (POBA) for the Treatment of Superficial Femoral Artery (SFA) In-Stent Restenosis Completed NCT01108861 Phase 4
46 Physician Initiated Multi-center Belgian-Italian-Dutch Trial Investigating Abbott Vascular Iliac Stents in the Treatment of TASC A, B, C & D Iliac Lesions Completed NCT00764777 Phase 4
47 Physician Initiated Trial Investigating the Efficacy of the Implant of EverFlex 200mm Long Nitinol Stents in TASC C&D Femoropopliteal Lesions Completed NCT00637741 Phase 4
48 Physician-Initiated PMCF Trial Investigating the BeGraft Peripheral Stent Graft System for the Treatment of Iliac Lesions Completed NCT02211716 Phase 4
49 Evaluation of Cilostazol in Combination With L-Carnitine in Subjects With Intermittent Claudication Completed NCT00822172 Phase 4 cilostazol
50 Prospective, Non-randomized Multi-center, Controlled Physician-initiated Trial: Rotarex Belgium In-stent Occlusion Completed NCT02212626 Phase 4

Search NIH Clinical Center for Vascular Disease

Inferred drug relations via UMLS 71 / NDF-RT 51 :


Baclofen

Cochrane evidence based reviews: aneurysm

Genetic Tests for Vascular Disease

Anatomical Context for Vascular Disease

MalaCards organs/tissues related to Vascular Disease:

40
Endothelial, Kidney, Smooth Muscle, Brain, Heart, Spinal Cord, Skin

Publications for Vascular Disease

Articles related to Vascular Disease:

(show top 50) (show all 40740)
# Title Authors PMID Year
1
MicroRNA-145, a novel smooth muscle cell phenotypic marker and modulator, controls vascular neointimal lesion formation. 47 61
19542014 2009
2
MicroRNA expression signature and antisense-mediated depletion reveal an essential role of MicroRNA in vascular neointimal lesion formation. 61 47
17478730 2007
3
Prolonged blockade of VEGF receptors does not damage retinal photoreceptors or ganglion cells. 54 61
20232317 2010
4
EGCG protects against oxidized LDL-induced endothelial dysfunction by inhibiting LOX-1-mediated signaling. 61 54
20203069 2010
5
Diagnosis and treatment of apolipoprotein B dyslipoproteinemias. 61 54
20421882 2010
6
Notch and transforming growth factor-beta (TGFbeta) signaling pathways cooperatively regulate vascular smooth muscle cell differentiation. 61 54
20368328 2010
7
Migraine and coronary artery disease: an open study on the genetic polymorphism of the 5, 10 methylenetetrahydrofolate (MTHFR) and angiotensin I-converting enzyme (ACE) genes. 54 61
20518725 2010
8
Aldose reductase and cardiovascular diseases, creating human-like diabetic complications in an experimental model. 61 54
20466987 2010
9
Microvascular complications are associated with low levels of maternal sE-selectin and sVCAM-1 in pregnancy complicated with pregestational diabetes mellitus. 61 54
20129688 2010
10
Hypoxia-inducible factor-1-dependent mechanisms of vascularization and vascular remodelling. 61 54
20164116 2010
11
Evidence for the efficacy of ARBs across the cardiovascular continuum. 61 54
20302552 2010
12
Plasminogen activator inhibitor-1 is an aggregate response factor with pleiotropic effects on cell signaling in vascular disease and the tumor microenvironment. 54 61
20079523 2010
13
Genetic variants promoting smooth muscle cell proliferation can result in diffuse and diverse vascular diseases: evidence for a hyperplastic vasculomyopathy. 54 61
20130469 2010
14
Association of apolipoprotein B with incident type 2 diabetes in an aboriginal Canadian population. 54 61
20110448 2010
15
Weighting the potential of using tenascin C in diagnosis and therapy of atherosclerosis. 54 61
20513936 2010
16
Vascular oxidative stress: the common link in hypertensive and diabetic vascular disease. 61 54
20422735 2010
17
Upregulation of heme oxygenase-1 inhibits the maturation and mineralization of osteoblasts. 54 61
20020468 2010
18
APOH is increased in the plasma and liver of type 2 diabetic patients with metabolic syndrome. 61 54
19878946 2010
19
JNK-ATF-2 inhibits thrombomodulin (TM) expression by recruiting histone deacetylase4 (HDAC4) and forming a transcriptional repression complex in the TM promoter. 54 61
20116378 2010
20
High glucose and elevated fatty acids suppress signaling by the endothelium protective ligand angiopoietin-1. 54 61
20079751 2010
21
Visfatin, glucose metabolism and vascular disease: a review of evidence. 54 61
20346149 2010
22
Endothelial nitric oxide synthase and nicotinamide adenosine dinucleotide phosphate oxidase p22phox gene (C242T) polymorphisms and systemic lupus erythematosus in a Chinese Population. 54 61
19965945 2010
23
The association between the -374T/A polymorphism of the receptor for advanced glycation endproducts gene and blood pressure and arterial stiffness is modified by glucose metabolism status: the Hoorn and CoDAM studies. 61 54
20051912 2010
24
Haptoglobin phenotype correlates with the extent of cerebral deep white matter lesions in hypertensive patients. 61 54
20158468 2010
25
An overview of the Guangzhou biobank cohort study-cardiovascular disease subcohort (GBCS-CVD): a platform for multidisciplinary collaboration. 54 61
19587700 2010
26
The connection between C-reactive protein (CRP) and diabetic vasculopathy. Focus on preclinical findings. 61 54
20034371 2010
27
The impact of macrophage insulin resistance on advanced atherosclerotic plaque progression. 54 61
20056946 2010
28
Telmisartan in high-risk cardiovascular patients. 61 54
20102972 2010
29
Impaired vascular endothelial growth factor signaling in the pathogenesis of neonatal pulmonary vascular disease. 61 54
20204740 2010
30
Paraoxonase 1 status as a risk factor for disease or exposure. 54 61
20221868 2010
31
Genetic predisposition to advanced glycation end products toxicity is related to prognosis of chronic hemodialysis patients. 61 54
20185929 2010
32
C-reactive protein gene variant and the human left ventricular growth response to exercise: data from The LARGE Heart Study. 54 61
19834334 2010
33
The protective role of adiponectin in pulmonary vascular disease. 61 54
19880503 2010
34
Plasma homocysteine, apolipoprotein E status and vascular disease in elderly patients with mental illness. 54 61
19943806 2010
35
Non-arteritic anterior ischemic optic neuropathy (NA-AION) after intravitreal injection of bevacizumab (Avastin) for treatment of angoid streaks in pseudoxanthoma elasticum. 54 61
19916212 2009
36
Homocysteine promotes vascular smooth muscle cell migration by induction of the adipokine resistin. 61 54
19828833 2009
37
Adenosine blocks IFN-gamma-induced phosphorylation of STAT1 on serine 727 to reduce macrophage activation. 61 54
19846878 2009
38
Distribution of endothelial nitric oxide synthase gene polymorphisms in Turkish population. 54 61
19730129 2009
39
Association of serum osteoprotegerin with ankle-brachial index and urine albumin: creatinine ratio in African-Americans and non-Hispanic whites. 61 54
19423112 2009
40
Coordinated regulation of angiopoietin-1 and vascular endothelial growth factor by arsenite in human brain microvascular pericytes: implications of arsenite-induced vascular dysfunction. 54 61
19622383 2009
41
Insulin glargine reduces carotid intimal hyperplasia after balloon catheter injury in Zucker fatty rats possibly by reduction in oxidative stress. 54 61
19360379 2009
42
Investigation of SERPINE1 genetic polymorphism in Macedonian patients with occlusive artery disease and deep vein thrombosis. 54 61
20017074 2009
43
Tissue factor gene polymorphisms and haplotypes and the risk of ischemic vascular events: four studies and a meta-analysis. 61 54
19583819 2009
44
Thrombin induces the expression of oncostatin M via AP-1 activation in human macrophages: a link between coagulation and inflammation. 61 54
19652200 2009
45
Endoglin haploinsufficiency reduces radiation-induced fibrosis and telangiectasia formation in mouse kidneys. 61 54
19576647 2009
46
Safety and tolerability of bosentan in the management of pulmonary arterial hypertension. 54 61
19920927 2009
47
Paraoxonase variants relate to 10-year risk in coronary artery disease: impact of a high-density lipoprotein-bound antioxidant in secondary prevention. 54 61
19778663 2009
48
Aspirin reduces the prothrombotic activity of C-reactive protein. 61 54
19522741 2009
49
Haemostatic markers are associated with measures of vascular disease in adults with hypertension. 61 54
19190656 2009
50
A-G-4G haplotype of PAI-1 gene polymorphisms -844 G/A, HindIII G/C, and -675 4G/5G is associated with increased risk of ischemic stroke caused by small vessel disease. 54 61
19154538 2009

Variations for Vascular Disease

Expression for Vascular Disease

Search GEO for disease gene expression data for Vascular Disease.

Pathways for Vascular Disease

GO Terms for Vascular Disease

Cellular components related to Vascular Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.96 VWF VEGFA SERPINE1 PON1 INS EDN1
2 extracellular exosome GO:0070062 9.73 VWF VCAM1 SERPINE1 PON1 MIR21 MIR146A
3 extracellular vesicle GO:1903561 9.67 MIR214 MIR21 MIR125A APOE
4 platelet alpha granule lumen GO:0031093 9.61 VWF VEGFA SERPINE1
5 extracellular space GO:0005615 9.53 VWF VEGFA VCAM1 SERPINE1 SELP PON1
6 Weibel-Palade body GO:0033093 9.4 VWF EDN1
7 high-density lipoprotein particle GO:0034364 9.33 PON1 APOE APOB
8 intermediate-density lipoprotein particle GO:0034363 9.32 APOE APOB

Biological processes related to Vascular Disease according to GeneCards Suite gene sharing:

(show all 41)
# Name GO ID Score Top Affiliating Genes
1 gene silencing by miRNA GO:0035195 10.02 MIR214 MIR21 MIR146A MIR145 MIR143 MIR125A
2 positive regulation of cell migration GO:0030335 9.98 VEGFA MIR21 INS EDN1
3 positive regulation of protein kinase B signaling GO:0051897 9.95 VEGFA MIR21 MIR143 INS
4 response to hypoxia GO:0001666 9.93 VEGFA VCAM1 MTHFR EDN1
5 negative regulation of cell migration GO:0030336 9.88 SERPINE1 MIR214 MIR21 MIR145
6 cellular response to hypoxia GO:0071456 9.84 VEGFA MIR214 MIR146A EDN1
7 regulation of blood pressure GO:0008217 9.83 NOS3 EDN1 ACE
8 positive regulation of endothelial cell migration GO:0010595 9.83 VEGFA MIR21 EDN1
9 platelet degranulation GO:0002576 9.81 VWF VEGFA SERPINE1 SELP
10 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.8 MIR214 MIR21 EDN1
11 positive regulation of blood vessel endothelial cell migration GO:0043536 9.8 VEGFA NOS3 MIR143
12 response to lipopolysaccharide GO:0032496 9.77 VCAM1 SELP NOS3 EDN1 APOB
13 positive regulation of gene expression GO:0010628 9.76 VEGFA NOS3 MIR21 MIR146A MIR125A INS
14 negative regulation of endothelial cell proliferation GO:0001937 9.73 MIR21 MIR146A APOE
15 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.71 VEGFA SELP MIR21